NAD+
MetabolicEndocrine and metabolic applications of NAD+ span direct incretin-axis engagement, AMPK and mitochondrial signalling, and adiposity-driven inflammation. The fundamental redox cofactor and substrate for sirtuins and PARPs — declining levels with age are a hallmark of metabolic aging. The Hours; cellular pool dynamic pharmacokinetic profile and iv/subq/intranasal/oral precursors (nr/nmn) administration shape the rate at which glycemic markers move; the typical NAD+ effect window in metabolic syndrome populations is 8-12 weeks.
Key Takeaways
Metabolic lens: NAD+ is tracked against glycemic, insulin sensitivity, visceral adiposity, and inflammatory markers. Mechanism: Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Metabolic monitoring: baseline HbA1c, fasting glucose, fasting insulin, HOMA-IR, hsCRP, ALT/AST; ideally CGM in first cycle. Metabolic dose: 100-1000 mg 1x weekly iv; daily subq at lower doses via iv/subq/intranasal/oral precursors (nr/nmn). Metabolic-medicine stack partners: Semaglutide (GLP-1), Cagrilintide, MOTS-c.
For metabolic-medicine applications, the relevant question is which of the four primary axes NAD+'s mechanism engages: incretin-amylin, AMPK-mitochondrial, visceral-fat-cardiometabolic, or the appetite-and-satiety circuit. Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Critically, NAD+ is the substrate consumed by sirtuins (SIRT1-7) and PARPs — both depend on adequate NAD+ for their longevity- and DNA-repair-related functions. NAD+ levels decline approximately 50% from age 20 to 60. The subsections below address each in turn.
Insulin signalling and glycemic effect
NAD+'s relationship to insulin signalling is one of the central practical considerations. Direct incretin-axis effects are limited, but downstream insulin sensitivity is influenced through inflammatory, mitochondrial, or weight-related mechanisms. The implication for glycemic monitoring is clear: baseline HbA1c, fasting glucose, and — ideally — a CGM during the first cycle for users in or near the diabetes-spectrum range.
Visceral fat and the cardiometabolic axis
NAD+'s effect on visceral adipose tissue, hepatic steatosis, and cardiometabolic risk indices is the dimension most clinically tracked. Visceral adipose effects emerge gradually over months of consistent dosing rather than acutely. The most-tracked markers are waist circumference, ALT/AST (hepatic), hsCRP (inflammation), and — where available — DEXA-quantified visceral fat.
Weight management and the appetite circuit
Direct appetite effects are not the principal mechanism, but downstream effects on inflammation and metabolic flexibility translate into sustainable rather than rapid weight management. Pairing with adequate protein intake and resistance training is the standard approach for users targeting weight reduction.
In the metabolic syndrome population, NAD+ for insulin sensitivity produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.
Where NAD+ is used for gastric emptying, integration with GLP-1 agonist therapy, AMPK activators, or visceral-fat-selective agents is the standard pattern in metabolic medicine clinics. Mono-therapy is appropriate for first-cycle users and for milder presentations.
NAD+ for metabolic syndrome is best-evaluated against baseline metabolic markers: fasting glucose, HbA1c, lipid panel, hsCRP, ALT/AST. Response timelines are typically 8–12 weeks for primary endpoints; secondary markers (inflammation, hepatic function) move on similar timescales.
In the metabolic syndrome population, NAD+ for fatty liver research produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | IV | 100-1000 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | IV | 60-1000 mg | 4–6 weeks initial cycle |
| Metabolic focus | IV | 100-1000 mg | 1x weekly IV; daily SubQ at lower doses |
| Maintenance phase | IV | 70-1000 mg | Ongoing with periodic pauses |
Dose timing for NAD+ is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
NAD+ stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from metabolic medicine specialists.
- NAD+ + Semaglutide (GLP-1): Selective GLP-1 receptor agonist. Pairs naturally with NAD+'s mechanism in metabolic / endocrine protocols.
- NAD+ + Cagrilintide: Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Pairs naturally with NAD+'s mechanism in metabolic / endocrine protocols.
- NAD+ + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with NAD+'s mechanism in metabolic / endocrine protocols.
- NAD+ + Tesamorelin: Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage. Pairs naturally with NAD+'s mechanism in metabolic / endocrine protocols.
Flushing common with IV (rate-dependent). Mild GI upset. Pretreatment with niacinamide can reduce flush.
Lens-specific safety considerations for metabolic / endocrine use of NAD+: Flushing common with IV (rate-dependent). Mild GI upset. Pretreatment with niacinamide can reduce flush. Additional metabolic / endocrine monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| NAD+ | Pyridine nucleotide cofactor | Hours; cellular pool dynamic | Metabolic |
| Semaglutide (GLP-1) | GLP-1 receptor agonist | ~7 days | The blockbuster GLP-1 receptor agonist with weekly dosing — engineered from native GLP-1 for protease resistance and albumin binding |
| Cagrilintide | Long-acting amylin analogue | ~7 days | A long-acting amylin analogue paired with semaglutide for weight loss results that exceed either drug alone |
| Tesamorelin | Stabilised GHRH analogue | ~30 min | An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction |
Pancreatitis or thyroid risk?
Will NAD+ affect my muscle mass during weight loss?
How does NAD+ affect glycemic control?
What weight loss can I expect?
Is NAD+ safe during pregnancy or breastfeeding?
What route should I use for NAD+?
Start a NAD+ Protocol
Alukard provides physician-supervised metabolic protocols with GMP-certified NAD+ and GMP-certified compounds with comprehensive metabolic and glycemic monitoring.
Get ProtocolQuick Facts
- Molecular weight
- 663 Da
- Half-life
- Hours; cellular pool dynamic
- WADA
- Not on prohibited list
- FDA
- Approved by various routes for various uses; mass-dose IV is off-label
Stack Partners
All metabolic / endocrine applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for NAD+ unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Metabolic / Endocrine Protocol for NAD+
Alukard provides physician-supervised metabolic protocols with GMP-certified compounds with comprehensive metabolic and glycemic monitoring.
HIPAA Compliant · GMP Certified · Physician Supervised